A geno-clinical model used mutational data and peripheral blood counts to accurately distinguish myelodysplastic syndromes from other myeloid malignancies.
An analysis of data from the NIH-AARP Diet and Health Study evaluated the association between consumption of various foods and the development of MPN.
An evaluation of more than 2 dozen types of integrative medicine therapies demonstrated that patients with MPNs who engaged in these activities had improved negative symptoms and quality of life.
A new meta-analysis indicates that the true prevalence of pulmonary hypertension linked to myeloproliferative neoplasms is not well understood.
A small, single-arm, phase 2 study results demonstrate efficacy and safety of this combination therapy in patients with MPN-AP or MPN-BP.
Investigators summarized current literature surrounding the diagnosis and risk-stratification of PV and ET, and reviewed available and upcoming therapies.
Some pointers from a review of assessment and management strategies for nurses caring for patients with polycythemia vera.
Using validated tools, investigators determined that patients with a MPN were likely to experience significant symptoms of depression.
Venetoclax, a BCL2 inhibitor, used in combination with a HMA improved outcomes in a cohort of 9 patients with AML secondary to MPN.
Interferon-alpha and pegylated interferon-alpha, as well as hydroxyurea and anagrelide, represent cytoreductive approaches to the treatment of patients with ET and PV.
